$139 Million is the total value of New Leaf Venture Partners, L.L.C.'s 14 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WVE | WAVE LIFE SCIENCES LTD | $25,462,000 | +56.9% | 784,159 | 0.0% | 18.33% | +31.3% | |
| VSAR | VERSARTIS INC | $24,980,000 | +10.8% | 2,039,223 | 0.0% | 17.98% | -7.3% | |
| EDGE | EDGE THERAPEUTICS INC | $24,410,000 | +3.0% | 2,344,868 | 0.0% | 17.57% | -13.8% | |
| OXFD | OXFORD IMMUNOTEC GLOBAL PLC | $17,301,000 | +39.6% | 1,377,497 | 0.0% | 12.46% | +16.8% | |
| DMTX | DIMENSION THERAPEUTICS INC | $16,454,000 | +33.2% | 2,059,283 | 0.0% | 11.85% | +11.4% | |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $7,568,000 | +58.9% | 230,954 | +21.0% | 5.45% | +32.9% |
| DERM | Sell | DERMIRA INC | $6,559,000 | +14.1% | 193,944 | -1.3% | 4.72% | -4.5% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $6,110,000 | +29.2% | 132,674 | -15.5% | 4.40% | +8.1% |
| DVAX | Sell | DYNAVAX TECHNOLOGIES CORP | $4,200,000 | -36.7% | 400,381 | -12.0% | 3.02% | -47.0% |
| AVEO | AVEO PHARMACEUTICALS INC | $2,306,000 | -7.4% | 2,590,673 | 0.0% | 1.66% | -22.5% | |
| VTGN | VISTAGEN THERAPEUTICS INC | $1,493,000 | +8.4% | 352,950 | 0.0% | 1.08% | -9.3% | |
| TRILLIUM THERAPEUTICS INC | $1,193,000 | +64.6% | 80,759 | 0.0% | 0.86% | +37.7% | ||
| ITEK | New | INOTEK PHARMACEUTICALS CORP | $477,000 | – | 50,300 | +100.0% | 0.34% | – |
| ADAP | Sell | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $388,000 | -62.5% | 55,008 | -56.7% | 0.28% | -68.7% |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -222,947 | -100.0% | -1.29% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 25 | Q3 2023 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ARVINAS INC | 21 | Q3 2023 | 44.8% |
| CRINETICS PHARMACEUTICALS INC | 21 | Q3 2023 | 11.4% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
| HARPOON THERAPEUTICS INC | 19 | Q3 2023 | 20.0% |
| ALECTOR INC | 19 | Q3 2023 | 4.6% |
| ITERUM THERAPEUTICS PLC | 18 | Q3 2022 | 3.8% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-11 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.